Advantages of Banking Naturally Derived Stem Cells vs. Alternatives

You are here: Home » Clinical Updates » Advantages of Banking Naturally Derived Stem Cells vs. Alternatives

Banking naturally collected stem cells from sources such as cord blood, cord tissue, and teeth provides unmatched biological quality, regulatory acceptance, and cost-effectiveness compared to alternatives like iPSCs or later-life invasive collections. The non-invasive nature and therapeutic readiness of these cells make them an invaluable resource for addressing future health needs. There are many reasons why this is the case:

1. Superior Quality of Naturally Collected Stem Cells

  • Stem cells collected from cord blood, cord tissue, and dental pulp at various life stages (birth, childhood, and young adulthood) are naturally sourced, naïve, and non-manipulated. These cells retain their original potency and purity, making them biologically superior for therapeutic applications.
  • Minimal Exposure to Environmental Damage: Cells sourced during childhood (e.g., from milk teeth or wisdom teeth extracted for orthodontic reasons) have limited exposure to environmental stressors like toxins and ageing-related mutations, which degrade cellular quality over time.
  • Natural Pluripotency: These cells are not genetically modified, avoiding concerns associated with induced pluripotency. (Pettit et al., Stem Cells International, 2018)1

2. Non-Invasive and Cost-Effective Collection

  • Collecting stem cells from teeth is a non-invasive process, typically occurring when a child naturally loses their milk teeth. However, extractions for orthodontic purposes can offer the opportunity to store later in life. This reduces the cost and eliminates risks associated with more invasive methods, like bone marrow aspiration, required to collect stem cells in adulthood.
  • The process utilises material that would otherwise be discarded, providing a convenient source of stem cells.

3. Limitations of Acquiring Stem Cells Later in Life

  • Decline in Stem Cell Quality with Age: Stem cells collected in adulthood could be less effective due to cumulative DNA damage, reduced proliferative capacity, and higher risk of senescence. (Wagner et al., Stem Cell Research, 2009)2
  • Invasiveness and Expense: Adult stem cells are often collected through painful and costly procedures, such as bone marrow extraction or liposuction for MSCs.
  • Compatibility Risks: Autologous cells collected later may carry latent genetic mutations or other age-related defects that could limit their therapeutic use.

4. iPSCs: A Promising but Flawed Alternative

  • Induced pluripotent stem cells (iPSCs) are created by reprogramming somatic cells to a pluripotent state. While this technology offers potential, it faces significant challenges:
    • Tumorigenicity: iPSCs have a high risk of forming teratomas (tumours) when transplanted. (Martinez-Fernandez et al., Nature Biotechnology, 2020)3
    • Genetic Modifications: The reprogramming process involves genetic manipulation, which may introduce unintended mutations or alter cellular behaviour, raising ethical and safety concerns. (Knoepfler et al., Trends in Molecular Medicine, 2013)4
    • Regulatory Hurdles: iPSCs are not yet widely accepted for clinical use due to concerns over their stability and long-term safety. In contrast, naturally collected cells (e.g., from cord blood or teeth) are already approved and successfully used in various treatments.
    • Therapeutic Efficacy: iPSCs can show reduced efficacy due to incomplete maturation of the cells. (Cerneckis, J., Cai, H. & Shi, Y.,Sig Transduct Target Ther, 2024).5
    • Cost and Practicality: The manufacturing and quality assurance of iPSCs is an expensive, highly specialised process. To produce cells for autologous therapy would require the appropriate facilities and personnel to produce GMP-compliant cellular products. It has been estimated that it would cost approximately $800,000 to produce a clinical grade autologous iPSC-derived cellular product in compliance with current good manufacturing practice. (Doss MX, Sachinidis A., Cells. 2019).
      6

    5. Therapeutic Applications Favor Younger, Non-Manipulated Cells

    • Stem cells sourced from younger individuals (birth through young adulthood) offer superior regenerative capacity and lower risk of genetic or environmental defects.
    • Naturally collected cells have been proven effective in treating conditions like leukaemia, lymphoma, and neurological disorders, with ongoing research expanding their potential in regenerative medicine. (Squillaro et al., Frontiers in Cell and Developmental Biology, 2016)7
    • Immediate availability of banked cells from early life stages avoids delays and additional costs associated with harvesting or generating cells later in life.

    6. Practical and Economic Advantages of Early Banking

    • Banking stem cells from cord blood, tissue, or teeth ensures a supply of high-quality cells that are accessible for both autologous and allogeneic treatments (dependant on HLA match).
    • Cost Efficiency: Once stored, the need for expensive collection procedures later in life is eliminated. In contrast, collecting adult stem cells or generating iPSCs is costly and resource-intensive. (Sun et al., Biological Research for Nursing, 2020)8

References

1. Pettit, A. R., et al. (2018). “Characteristics of Cord Blood and Dental Pulp Stem Cells.” Stem Cells International.
Highlights the purity and regenerative potential of naturally collected stem cells.

2. Wagner, W., et al. (2009). “Replicative Senescence and Stem Cell Quality.” Stem Cell Research.
Discusses how stem cell quality declines with age.

3. Martinez-Fernandez, A., et al. (2020). “Challenges of iPSCs in Clinical Applications.” Nature Biotechnology.
Reviews tumor risks and genetic issues associated with iPSCs.

4. Knoepfler, P., et al. (2013). “The Safety of Induced Pluripotent Stem Cells.” Trends in Molecular Medicine.
Explores ethical and safety concerns of genetically modified stem cells.

5. Cerneckis, J., Cai, H. & Shi, Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Sig Transduct Target Ther 9, 112 (2024). https://doi.org/10.1038/s41392-024-01809-0

6. Doss MX, Sachinidis A. Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. Cells. 2019 Apr 30;8(5):403. doi: 10.3390/cells8050403. PMID: 31052294; PMCID: PMC6562607.